tbuckley/cabot-search huggingface dataset:
Development of a new micro-injection-system for adenoviral gene delivery (MAGD)
Authors: G. Bohlen, A. Raabe, J. Dahm-Daphi, E. Dikomey, S. E. Schild, J. Dunst, D. Rades
Journal: Journal of Clinical Oncology (2009)

e22167 Background: Safe and effective delivery of viral vectors is important for gene therapy. Local application of such vectors is more efficient than systemic application. However, currently available injection systems are not optimal because placement of the injection needle and the vector application itself are generally not reproducibile. We developed a new injection system providing controlled injection of adenoviral vectors in tumors (xeno-transplants) in nude mice (NMRI nu/nu). Methods: The new MAGD consists of two fixation devices mounted on a 40x40cm plexi-glass plate, four injection units, and one pump unit with 4 infusion-pumps (Bee hive, Bioanalytical, Chesire, UK). Each injection unit is linked to a pump with commercially available plastic tube. Because the injection arms can be moved in x-,y- and z-direction, virus injection can easily performed for irregular tumor volumes. The entire injection volume is equally distributed to the 4 injection pumps allowing precise and steady injection rates between 0.1μl/min and 100μl/min. Success was confirmed with MRI-scans (Magnetom symphony, Siemens, Erlangen, Germany) 10 min after the injection. The efficacy of the MAGD was tested in 4 human squamous cell carcinoma cell lines from oro-/hypopharynx (FaDu, UD- SCC2, UD-SCC6, and UD-SCC7a). Virus transfection was performed with an adenovirus (serotype 5) expressing enhanced green fluorescent protein (eGFP). Transfection rates were quantified with flow cytometry. Successfully transfected cells expressed eGFP resulting in green fluorescence. In-vitro cell lines (concentration: 10 particles per cell, MOI 10) of FaDu, UD-SCC2, UD-SCC6 and UD-SCC7a served as controls. Results: The MAGD was easy to handle. Injection of 100μl (25μl per infusion pump) at an injection rate of 5μl/min took only 5 min. The in-vivo transfection rates achieved with the MAGD were 9±1% for FaDu, 39±2% for UD- SCC, 54±1% for UD-SCC6 and 54±9% for UD-SCC7a, respectively. The in-vitro transfection rates (controls) for these 4 cell lines were 2±1%, 23±4%, 29±4% and 3±2%, respectively. Conclusions: The new MAGD provided controlled injection of adenoviral vectors in tumors in nude mice. It proved to be effective, as it resulted in comparably high transfection rates. No significant financial relationships to disclose.
The Influence of Amethopterin on the Survival Time of Leukemic Mice with Respect to Food Intake, Body Weight Changes, and Tumor Growth
Authors: Stewart R. Humphreys, Abraham Goldin, John M. Venditti, Nathan Mantel
Journal: JNCI Journal of the National Cancer Institute (1958)

The Influence of Amethopterin on the Survival Time of Leukemic Mice with Respect to Food Intake, Body Weight Changes, and Tumor Growth Get access Stewart R. Humphreys, Stewart R. Humphreys Laboratory of Chemical Pharmacology, and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Abraham Goldin, Abraham Goldin Laboratory of Chemical Pharmacology, and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar John M. Venditti, John M. Venditti Laboratory of Chemical Pharmacology, and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Nathan Mantel Nathan Mantel Laboratory of Chemical Pharmacology, and Biometry Branch, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 1, January 1958, Pages 211–218, https://doi.org/10.1093/jnci/20.1.211 Published: 01 January 1958 Article history Received: 16 August 1957 Published: 01 January 1958
166Ho-DOTMP Skeletal Targeted Radiotherapy with melphalan and autologous stem cell support for multiple myeloma
Authors: W. Bensinger, S. Giralt, M. Goodman, D. Salzman, K. Ruffner, H. Breitz
Journal: Journal of Clinical Oncology (2004)

6656 Background: 166Ho-DOTMP is a radiotherapeutic that localizes specifically to the skeleton and can deliver high dose radiation to the bone and marrow for skeletal targeted radiotherapy (STR). Follow-up data from 3 clinical trials of patients with multiple myeloma are presented. Methods: In 2 Phase I/II dose-escalation trials, 82 patients received a dose of 166Ho–DOTMP calculated to deliver 20, 30, or 40 Gy to the red marrow, plus melphalan (mel; 140 or 200 mg/m2) +/- 8 Gy TBI, followed by autologous stem cell transplant (PBSCT). As of 12/1/03, subjects have been followed for at least 38 months. In a separate Phase II dosimetry trial, 12 patients received 2 tracer doses of 166Ho-DOTMP to determine the reproducibility of biodistribution and pharmacokinetics (PK), followed by a 25 Gy therapy dose with continuous bladder irrigation, followed by 200 mg/m2 mel and PBSCT. These patients have been followed for at least 12 months. Results: Up to 2.3 Ci/m2 166Ho-DOTMP was given in the Phase I/II trials. 29/82 (35%) patients achieved complete response (CR) and ORR (CR + PR + SD) was 91% (7 pts not evaluable). Median duration of CR was > 24 months, and the Kaplan-Meyer estimate of 3 year survival was 60% for all 82 patients. Of 10 patients who received 750 mCi/m2 +/-10%, the CR rate was 40% and the 3-year survival was 90%. However, dose-related radiation-induced bladder and kidney toxicity appeared between 3 and 13 months post-therapy at high doses. Currently, 12 months of follow-up from the Phase II dosimetry trial shows no occurrence of hemorrhagic cystitis or elevated creatinine > Grade 2. The dose of 166Ho-DOTMP in this study was 550 to 860 mCi/m2. A CR rate of 17% was seen, and the biodistribution and PK of 166Ho-DOTMP were reproducible. Monitoring for safety and duration of response is ongoing for both trials. Conclusions: Follow-up from the Phase II dosimetry trial confirms that 750 mCi/m2 +/- 10% of 166Ho–DOTMP provides favorable efficacy and safety as part of the conditioning regimen for patients with multiple myeloma undergoing autologous PBSCT. A Phase III, multicenter, randomized trial with 750 mCi/m2 166Ho-DOTMP is planned to begin enrollment in Q1 of 2004. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration NeoRx NeoRx; PPD NeoRx NeoRx NeoRx, Inc.
Barriers to mammography among underserved women in a breast health center outreach program.
Authors: Oluwadamilola M. Fayanju, Susan Kraenzle, Bettina F. Drake, Xuemei Si, Masayoshi Oka, Melody S. Goodman
Journal: Journal of Clinical Oncology (2012)

13 Background: An outreach registry of Breast Health Center patients was developed in 2006 to evaluate the effectiveness of mobile mammography among the medically underserved. Registry included collection of medical record data, demographic data, and answers to a questionnaire about perceptions of breast cancer screening. Here, we examine barriers to mammography. Methods: Between April 2006 and May 2011, 9,082 women were registered. Data from registrants’ first screening visit (n= 8,916) were analyzed using multivariable logistic regression examining three outcomes identified as barriers to mammography: cost, fear of pain during the procedure, and fear of receiving bad news. Two-tailed p&lt;0.05 was considered significant. Results: The majority of registrants were black (54%), uninsured (74%), screened on a van (83%), resided in the greater St. Louis region (84%), had an annual income &lt;$20,000 (87%), and reported a good or excellent experience as part of the outreach program (92%). Fears of cost, mammogram-related pain, and bad news were reported by 40%, 13%, and 13% of registrants, respectively. Regression analyses revealed that being employed (odds ratio [OR] 1.109, p=0.0323) and living in the Bootheel of Missouri (OR 2.319, p&lt;0.0001) were associated with a higher likelihood of perceiving cost as a barrier to mammography, while those who had insurance (OR 0.439) and were Hispanic (compared to non-Hispanic [NH] whites [OR 0.338]) were less likely to report cost as a barrier (both p&lt;0.0001). Registrants who were screened on the van (OR 1.633), had insurance (OR 1.391), and were NH black (OR 1.324) were more likely to report fear of procedural pain as a barrier (all p&lt;0.0001). Having insurance (OR 1.378), being NH black (OR 2.458), and being Hispanic (OR 2.980) were associated with reporting fear of receiving bad news as a barrier (all p&gt;0.0001), while older women (OR 0.985, p=0.0001) and women who were screened on the van (OR 0.772, p=0.0026) were less likely to report this concern. Conclusions: Despite provision of free services, cost, fear of procedural pain, and fear of abnormal results remain barriers to mammography utilization among medically underserved women, suggesting the need for more breast health education in this population.
Abstract 10727: Telmisartan Reduces Coronary Plaque Vulnerability and Instent-neointimal Proliferation in Hypertensive Patients
Authors: Koji Yamaguchi, Tetsuzo Wakatsuki, Takeshi Soeki, Toshiyuki Niki, Yoshio Taketani, Hiroyasu Oeduka, Mika Bando, Kozue Ogasawara, Sachiko Bando, Jyunko Hotchi, Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Masataka Sata
Journal: Circulation (2012)
AIDS-related lymphadenopathy: the role of biopsy.
Authors: D I Abrams
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.2.126 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3944602 AIDS-related lymphadenopathy: the role of biopsy. D I AbramsxD I AbramsSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.2.126 PDF "AIDS-related lymphadenopathy: the role of biopsy.." Journal of Clinical Oncology, 4(2), pp. 126–127© 1986 by American Society of Clinical Oncology
Abstract 13563: N-terminal Probrain Natriuretic Peptide and its Relation With Cardiac Dysfunction in Adult Patients With Congenital Heart Disease
Authors: Jannet A Eindhoven, Annemien E van den Bosch, Titia P Ruys, Petra Opic, Judith A Cuypers, Jackie S McGhie, Maarten Witsenburg, Eric Boersma, Jolien Roos-Hesselink
Journal: Circulation (2013)

Introduction: Although life expectancy has improved dramatically, most patients with congenital heart disease (CHD) are at risk to develop late complications including heart failure. Early detection of cardiac dysfunction may play a pivotal role. Objectives: The aim of this study was to determine the relation between echocardiography and NT-proBNP in adults with CHD to improve cardiac function assessment. Methods: Extensive 2D-echocardiography and NT-proBNP measurements were performed on the same day in adult CHD patients. The included CHD were corrected atrial septal defect (ASD) and aortic coarctation (CoA), corrected and uncorrected aortic stenosis (AoS), tetralogy of Fallot (ToF), transposition of the great arteries corrected by Mustard surgery or arterial switch operation (ASO) and Fontan circulation. Results: We included 475 patients (age 34±12 years, 57% male, 90% NYHA I). Median NT-proBNP was 15.1 [IQR 24.2] pmol/L (elevated in 53%). Highest NT-proBNP levels were observed in complex CHD, comprisin...
Abstract 15976: Results of the Full Cox-Maze Procedure: EKG vs 24-Hour Holter vs One-Week Long-Term Holter Monitoring
Authors: Niv Ad, Lori E Stone, Sari D Holmes
Journal: Circulation (2014)

Introduction: Much of work published on Cox-Maze procedure results has utilized EKGs or 24-hour Holter without information on anti-arrhythmic drugs (AAD). The purpose of this study was to explore results at 6 and 24 months following the Cox-Maze procedure using various rhythm monitoring techniques. Hypothesis: It was hypothesized that long-term monitoring (LTM) would identify more patients who experienced atrial arrhythmia (AA) at each time point than other monitoring techniques. Methods: Cox-Maze III/IV patients off AAD were offered 1-week LTM with n=220 at 6 and n=94 at 24 months. EKG, 24-hour Holter, and LTM were ascertained at the same time. The HRS definition (AA &gt;30 seconds) was used for ablation failure. Results: At 6 months EKG found n=216 returned to sinus rhythm (SR), 24-hr Holter found n=211 returned to SR, while n=203 were in SR by LTM (FIGURE). Of patients experiencing AA at 6 months, duration &lt;1 hour was documented in 56% by 24-hr Holter and 59% by LTM (FIGURE). At 24 months, EKG found n=89 returned to SR, 24-hr Holter found n=88 returned to SR, while n=85 were in SR by LTM. Of patients experiencing AA at 24 months, duration &lt;1 hour was documented in 50% by 24-hr Holter and 67% by LTM. At 6 months, percent in SR differed for EKG vs LTM (p&lt;0.001) and 24-hr Holter vs LTM (p=0.02). At 24 months, monitoring methods did not differ. Conclusions: The Cox-Maze procedure demonstrated high return to SR off AAD, regardless of monitoring technique. However, LTM provides more accuracy earlier in postoperative period and should be used when discussing discontinuation of anticoagulation. Due to clinical and financial challenges in applying LTM, patients in which LTM has most value should be identified.
Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort
Authors: Eric J Chow, Kayla L Stratton, Wendy M Leisenring, Kevin C Oeffinger, Charles A Sklar, Sarah S Donaldson, Jill P Ginsberg, Lisa B Kenney, Jennifer M Levine, Leslie L Robison, Margarett Shnorhavorian, Marilyn Stovall, Gregory T Armstrong, Daniel M Green
Journal: The Lancet Oncology (2016)
Benefit/Risk Ratio of New Drugs: For whom? Discussion Paper
Authors: R Palminteri
Journal: Journal of the Royal Society of Medicine (1988)

In an attempt to assess whether there are any characteristics which a majority of ordinary people regard as life-affirming or life-denying, a questionnaire was given to a pilot group of 167 respondents, representing three different age and social categories. Five life-affirming and five life-denying characteristics were mentioned by more than 10% of respondents. Of the former, Drive, Sociability, Happiness and Optimism were endorsed by 15-20%. Of the latter, Unsociability and Poor Coping were mentioned by 22%, making them distinctly more frequent than the following categories of Pessimism, Lack of Drive and Unhappiness (11-14%). It is suggested that a number of these subjectively determined characteristics, which the general public perceive as being life-affirming or denying, do indeed influence physical or mental health, illness or illness behaviour. It may therefore be of value to utilize this set of public perceptions in future programmes of health education.
Carcinogenicity of Extracts of Selected Plants From Curacao After Oral and Subcutaneous Administration to Rodents&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: O'Gara, Roger W., Lee, Cecil, Morton, Julia F.
Journal: JNCI Journal of the National Cancer Institute (1971)

Journal Article Carcinogenicity of Extracts of Selected Plants From Curacao After Oral and Subcutaneous Administration to Rodents Get access Roger W. O'Gara, Roger W. O'Gara Laboratory of Pathology, National Cancer Institute,5Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Cecil Lee, Cecil Lee Laboratory of Pathology, National Cancer Institute,5Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Julia F. Morton Julia F. Morton Laboratory of Pathology, National Cancer Institute,5Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 46, Issue 6, June 1971, Pages 1131–1137, https://doi.org/10.1093/jnci/46.6.1131 Published: 01 June 1971 Article history Received: 24 March 1971 Accepted: 29 March 1971 Published: 01 June 1971
Clinical benefit as a primary efficacy endpoint.
Authors: E Ballatori, A Del Favero, F Roila
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.2.803 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9469377 Clinical benefit as a primary efficacy endpoint. E BallatorixE BallatoriSearch for articles by this author , A Del FaveroxA Del FaveroSearch for articles by this author , F RoilaxF RoilaSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.2.803 PDF "Clinical benefit as a primary efficacy endpoint.." Journal of Clinical Oncology, 16(2), pp. 803–804© 1998 by American Society of Clinical Oncology
Morphologic Changes and Immunohistochemical Localization of Adenosine Deaminase in Tissues of Rats Given Injections of 2'-Deoxycoformycin&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: B E Checkik, A Perets, S SenGupta, B Fernandes
Journal: JNCI Journal of the National Cancer Institute (1983)

2'-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent. In this study the kinetics of ADA expression was assessed by immunomorphologic and enzymatic methods in tissues of ACI rats given injections of DCF. The rats received a daily ip injection of 10 mg DCF/kg for 3 consecutive days. This treatment destroyed cortical thymocytes, whereas lymphocytes of the thymic medulla were mainly preserved. In control phosphate-buffered saline-injected rats, cortical thymocytes were not affected morphologically and displayed strong ADA staining. It was found unexpectedly that injections of DCF produced activation and, possibly, differentiation of B-cells in the mesenteric lymph nodes and spleen. These activated B-lymphocytes and plasma cells stained strongly for ADA. Transient changes in patterns of ADA expression were also observed in endothelial cells of blood vessels and liver Kupffer's cells, but these changes were not accompanied by degeneration of the cells. The treatment with DCF did not result in any permanent abnormalities in the rat tissues.
Chronic Poliovirus Infection of Cocultivated Monkey Cells Harboring the Mason-Pfizer Monkey Virus<xref ref-type="fn" rid="FN1">2</xref>
Authors: W. A. Nelson-Rees, L. E. Hooser, A. J. Hackett
Journal: JNCI Journal of the National Cancer Institute (1972)

We studied a cell system (CMMT), consisting of embryonic rhesus monkey cells harboring the Mason-Pfizer monkey virus (M-PMV), periodically cocultivated with fresh embryonic rhesus cells before, but not after, our receipt of the culture. It contained cells that were either sensitive or completely resistant to cytolysis by poliovirus, types 1 and 3. Cultures derived from poliovirus-surviving cells (CMMT-P) continued to produce M-PMV and supported a low-grade, chronic infection with poliovirus. Karyology, isoenzyme analyses, specific immunoRuorescence tests, and ribosomal RNA values confirmed the primate origin of CMMT cells but could not distinguish between them and CMMT-P cells.
Estimating Contraceptive Needs and Increasing Access to Contraception in Response to the Zika Virus Disease Outbreak — Puerto Rico, 2016
Authors: Naomi K. Tepper, Howard I. Goldberg, Manuel I. Vargas Bernal, Brenda Rivera, Meghan T. Frey, Claritsa Malave, Christina M. Renquist, Nabal Jose Bracero, Kenneth L. Dominguez, Ramon E. Sanchez, Carrie K. Shapiro-Mendoza, Blanca R. Cuevas Rodriguez, Regina M. Simeone, Nicki T. Pesik, Wanda D. Barfield, Jean Y. Ko, Romeo R. Galang, Janice Perez-Padilla, Kara N.D. Polen, Margaret A. Honein, Sonja A. Rasmussen, Denise J. Jamieson
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Zika virus is a flavivirus transmitted primarily by Aedes species mosquitoes. Increasing evidence links Zika virus infection during pregnancy to adverse pregnancy and birth outcomes, including pregnancy loss, intrauterine growth restriction, eye defects, congenital brain abnormalities, and other fetal abnormalities. The virus has also been determined to be sexually transmitted. Because of the potential risks associated with Zika virus infection during pregnancy, CDC has recommended that health care providers discuss prevention of unintended pregnancy with women and couples who reside in areas of active Zika virus transmission and do not want to become pregnant. However, limitations in access to contraception in some of these areas might affect the ability to prevent an unintended pregnancy. As of March 16, 2016, the highest number of Zika virus disease cases in the United States and U.S. territories were reported from Puerto Rico. The number of cases will likely rise with increasing mosquito activity in affected areas, resulting in increased risk for transmission to pregnant women. High rates of unintended and adolescent pregnancies in Puerto Rico suggest that, in the context of this outbreak, access to contraception might need to be improved. CDC estimates that 138,000 women of reproductive age (aged 15-44 years) in Puerto Rico do not desire pregnancy and are not using one of the most effective or moderately effective contraceptive methods, and therefore might experience an unintended pregnancy. CDC and other federal and local partners are seeking to expand access to contraception for these persons. Such efforts have the potential to increase contraceptive access and use, reduce unintended pregnancies, and lead to fewer adverse pregnancy and birth outcomes associated with Zika virus infection during pregnancy. The assessment of challenges and resources related to contraceptive access in Puerto Rico might be a useful model for other areas with active transmission of Zika virus.